// App-Quantinova.ai

3001 : CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.

Researchers

Presenter

  • Matthew David Hellmann

Principal Investigators

  • Scott N. Gettinger

  • Jonathan Wade Goldman

  • Julie R. Brahmer

  • Hossein Borghaei

  • Laura Q. Chow

  • Neal Ready

  • David E. Gerber

  • Rosalyn A. Juergens

  • Frances A. Shepherd

  • Scott Andrew Laurie

  • Ye Zhou

  • William J. Geese

  • Shruti Agrawal

  • Xuemei Li

  • Scott Joseph Antonia

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Yale Comprehensive Cancer Center, New Haven, CT

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Fox Chase Cancer Center, Philadelphia, PA

  • University of Washington, Seattle, WA

  • Duke University Medical Center, Durham, NC

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Ottawa Hospital Cancer Center, University of Ottawa, Ottawa, ON, Canada

  • Bristol-Myers Sqiubb, Princeton, NJ

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01454102N1

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved